This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

7 Biotechnology Stocks With Insider Buying Activity

Biotech stocks can provide sudden and magnificent returns, but they can be just as unforgiving. How can you decide which biotech stocks are worth investing in then? We looked into it further: 

We ran a screen of biotech stocks that are showing insider buying. If anyone knows what is going on with a company, it has to be the people that work there.  [Related list:  Bullish Trinity: Stocks with Short Covering, Insider & Hedge Fund Buying ]

Many analysts follow insider buying trends exactly for that reason. Their transactions are closely monitored and can tell us a lot about where the business is heading.

Business Section: Investing Ideas

If insiders are buying the stock of the biotech company they’re working for, then they have to either think that the stock is undervalued or that something big is going to happen, such as a drug receiving FDA approval.

Below is the final list from our screen. It shows biotech companies with market caps over $50 million and insider buying over the past six months. Do you think the insiders know something that nobody else does?

Use this list as a starting point for your own analysis. 

1. Amyris, Inc. (AMRS , Earnings , Analysts , Financials ): An integrated renewable products company, offers renewable compounds for a variety of markets. Market cap at $217.5M.

Over the last six months, insiders were net buyers of 4,718,990 shares, which represents about 16.89% of the company's 27.94M share float.

2. Infinity Pharmaceuticals, Inc. (INFI, Earnings, Analysts, Financials): Engages in the discovery and development of medicines for the treatment of cancer and other conditions in the United States. Market cap at $2.34B.

Over the last six months, insiders were net buyers of 5,380,195 shares, which represents about 18.43% of the company's 29.19M share float.

3. Lexicon Pharmaceuticals, Inc. (LXRX, Earnings, Analysts, Financials): Focuses on the discovery and development of drug candidates for the treatment of various human diseases. Market cap at $1.11B.

Over the last six months, insiders were net buyers of 3,000,000 shares, which represents about 1.32% of the company's 227.31M share float.

4. MannKind Corp. (MNKD, Earnings, Analysts, Financials): Focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer. Market cap at $972.54M.

Over the last six months, insiders were net buyers of 39,997,650 shares, which represents about 32.04% of the company's 124.82M share float.

5. Pacific Biosciences of California, Inc. (PACB, Earnings, Analysts, Financials): Develops, manufactures, and markets an integrated platform for genetic analysis. Market cap at $124.11M.

Over the last six months, insiders were net buyers of 1,400,000 shares, which represents about 4.26% of the company's 32.84M share float.

6. Targacept, Inc. (TRGT, Earnings, Analysts, Financials): Engages in the design, discovery, and development of novel Neuronal Nicotinic Receptors (NNR) Therapeutics for the treatment of diseases and disorders of the central nervous system. Market cap at $148.22M.

Over the last six months, insiders were net buyers of 2,023,840 shares, which represents about 8.88% of the company's 22.78M share float.

7. XOMA Corporation (XOMA): Engages in the discovery, development, and manufacture of therapeutic antibodies to treat inflammatory, autoimmune, infectious, and oncological diseases. Market cap at $274.23M.

Over the last six months, insiders were net buyers of 4,722,670 shares, which represents about 9.76% of the company's 48.41M share float.

( List compiled by Rebecca Lipman, Kapitall Editor )


Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,081.89 -49.97 -0.29%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,796.6090 -42.0340 -0.87%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs